UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------ FORM 6-K ------------ REPORT OF FOREIGN ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 August 04, 2009 ------------ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) NOVO ALLE DK-2880, BAGSVAERD DENMARK (Address of principal executive offices) ------------ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [X] Form 40-F [ ] Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes [ ] No [X] If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________ TRANSACTION IN OWN SHARES NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME On 29 January 2009, Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009. Since the announcement as of 27 July 2009, the following transactions have been made under the programme: AVERAGE TRANSACTION NUMBER OF PURCHASE VALUE, DKK SHARES PRICE ACCUMULATED, LAST ANNOUNCEMENT 9,950,382 2,778,221,354 27 July 2009 75,000 304.9250 22,869,375 28 July 2009 95,000 312.0840 29,647,980 29 July 2009 149,500 305.6500 45,694,675 30 July 2009 85,000 307.7800 26,161,300 31 July 2009 85,000 307.2900 26,119,650 ACCUMULATED UNDER THE PROGRAMME 10,439,882 2,928,714,334 With the transactions stated above, Novo Nordisk owns a total of 21,231,941 treasury shares, corresponding to 3.4% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com. Further information: Media: Investors: Outside North America: Outside North America: Elin K Hansen Mads Veggerby Lausten Tel: (+45) 4442 3450 Tel: (+45) 4443 7919 ekh@novonordisk.com mlau@novonordisk.com Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com In North America: In North America: Sean Clements Hans Rommer Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937 secl@novonordisk.com hrmm@novonordisk.com Company Announcement no 45 / 2009 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: August 04, 2009 NOVO NORDISK A/S --------------------------------------------------- Lars Rebien Sorensen, President and Chief Executive Officer